600332 Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
Closed 03-24 15:00:00
26.69
+0.09
+0.34%
High26.87Low26.55Vol8.11M
Open26.55D1 Closing26.60Amplitude1.20%
Mkt Cap43.40BTradable Cap37.53BTotal Shares1.63B
T/O216.00MT/O Rate0.58%Tradable Shares1.41B
P/B1.21ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
暂无数据
Baiyunshan Pharmaceutical Gets Nod to Outsource Ginger Granule Production
MT Newswires Live  ·  03-18
Baiyunshan Pharmaceutical Gets Nod to Outsource Ginger Granule Production
Guangzhou Baiyunshan Pharmaceutical Plans to Apply for Credit Line
MT Newswires Live  ·  03-14
Guangzhou Baiyunshan Pharmaceutical Plans to Apply for Credit Line
Baiyunshan Pharmaceutical 2024 Profit Down 30%, Revenue Slips 0.7%
MT Newswires Live  ·  03-14
Baiyunshan Pharmaceutical 2024 Profit Down 30%, Revenue Slips 0.7%
Baiyunshan Pharmaceutical Says 2024 Net Profit Down 30.1% Y/Y
THOMSON REUTERS  ·  03-13
Baiyunshan Pharmaceutical Says 2024 Net Profit Down 30.1% Y/Y
BRIEF-Baiyunshan Pharmaceutical's 2024 Net Profit Down 30.1% Y/Y
Reuters  ·  03-13
BRIEF-Baiyunshan Pharmaceutical's 2024 Net Profit Down 30.1% Y/Y
Baiyunshan Pharmaceutical's Branch Gets Nod to Market Atorvastatin Calcium
MT Newswires Live  ·  03-07
Baiyunshan Pharmaceutical's Branch Gets Nod to Market Atorvastatin Calcium
DIARY-China corporate earnings week ahead
Reuters  ·  03-07
DIARY-China corporate earnings week ahead
Baiyunshan Pharma's Unit Gets Regulatory Nod to Amend License
MT Newswires Live  ·  03-06
Baiyunshan Pharma's Unit Gets Regulatory Nod to Amend License
Guangzhou Baiyunshan Pharmaceutical - Disposal of Second New Underlying Assets of Gp Corp. to Industrial Securities Asset Management for RMB583.1 Mln
THOMSON REUTERS  ·  02-28
Guangzhou Baiyunshan Pharmaceutical - Disposal of Second New Underlying Assets of Gp Corp. to Industrial Securities Asset Management for RMB583.1 Mln
MORNING BID ASIA-Tariffs, tech fatigue rev up month-end turbulence
Reuters  ·  02-27
MORNING BID ASIA-Tariffs, tech fatigue rev up month-end turbulence
BRIEF-Guangzhou Baiyunshan Pharmaceutical Received Written Resignation From Executive Director
Reuters  ·  02-14
BRIEF-Guangzhou Baiyunshan Pharmaceutical Received Written Resignation From Executive Director
Guangzhou Baiyunshan Pharmaceutical - Received Written Resignation From Wu Changhai as Executive Director
THOMSON REUTERS  ·  02-14
Guangzhou Baiyunshan Pharmaceutical - Received Written Resignation From Wu Changhai as Executive Director
Baiyunshan Pharmaceutical Gets Regulatory Approval to Amend Drug Production License
MT Newswires Live  ·  02-13
Baiyunshan Pharmaceutical Gets Regulatory Approval to Amend Drug Production License
Guangzhou Baiyunshan Pharmaceutical Passes Generic Drug Evaluation for Antibiotic Drug
MT Newswires Live  ·  01-24
Guangzhou Baiyunshan Pharmaceutical Passes Generic Drug Evaluation for Antibiotic Drug
BRIEF-Guangzhou Baiyunshan Pharmaceutical Says Liu Juyan Resigns As Executive Director Of 9th Session
Reuters  ·  01-21
BRIEF-Guangzhou Baiyunshan Pharmaceutical Says Liu Juyan Resigns As Executive Director Of 9th Session
Guangzhou Baiyunshan Pharmaceutical - Received Resignation From Liu Juyan as Executive Director of 9TH Session
THOMSON REUTERS  ·  01-21
Guangzhou Baiyunshan Pharmaceutical - Received Resignation From Liu Juyan as Executive Director of 9TH Session
BRIEF-Guangzhou Baiyunshan Pharmaceutical Elects Chairman
Reuters  ·  01-21
BRIEF-Guangzhou Baiyunshan Pharmaceutical Elects Chairman
Guangzhou Baiyunshan Pharmaceutical Says Board Agrees to Elect Li Xiaojun as Chairman
THOMSON REUTERS  ·  01-21
Guangzhou Baiyunshan Pharmaceutical Says Board Agrees to Elect Li Xiaojun as Chairman
Guangzhou Baiyunshan Pharma Gets Local Approval to Reduce, Add Production Lines
MT Newswires Live  ·  01-16
Guangzhou Baiyunshan Pharma Gets Local Approval to Reduce, Add Production Lines
Baiyunshan Pharma's Venture Capital Fund Completes Registration
MT Newswires Live  ·  01-08
Baiyunshan Pharma's Venture Capital Fund Completes Registration

Introduction

Company Name.
广州白云山医药集团股份有限公司
Industry:
医药制造业
Listing Date:
2001-02-06
Main Business:
　　广州白云山医药集团股份有限公司的主营业务是中西成药、化学原料药、天然药物、生物医药、化学原料药中间体的研发、制造与销售；西药、中药和医疗器械的批发、零售和进出口业务；大健康产品的研发、生产与销售；医疗服务、健康管理、养生养老等健康产业投资。公司的主要产品是中成药、化学药。本集团及合营企业共获得国家科技进步奖1项，省级科技进步奖3项，其中白云山和黄公司“中药质量检测技术集成创新与支撑体系创建及应用”荣获“国家科学技术进步奖”。
Issue price:
9.80
Invest in Global Markets with Tiger Brokers!
Open App